Patents by Inventor Enxiu Wang

Enxiu Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
    Patent number: 11919946
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: March 5, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Michael C. Milone, Enxiu Wang
  • Chimeric antigen receptor carrying truncated or untruncated myeloid cell triggering receptor signaling structure and applications thereof
    Publication number: 20220280565
    Abstract: A chimeric antigen receptor (CAR) includes: an antigen-binding domain (scfv) and a signaling domain, wherein the signaling domain includes a first conducting domain and a second conducting domain; the antigen-binding domain is connected between the first conducting domain and the second conducting domain.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 8, 2022
    Inventors: Enxiu Wang, Chen Wang, Hai Zhang, Guoying Wu
  • TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
    Publication number: 20210079073
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Application
    Filed: April 1, 2020
    Publication date: March 18, 2021
    Inventors: Michael C. Milone, Enxiu Wang
  • TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
    Publication number: 20200377589
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Application
    Filed: January 15, 2020
    Publication date: December 3, 2020
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Michael C. Milone, Huijuan Song, Enxiu Wang, Qilong Wu
  • Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
    Patent number: 10640553
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: May 5, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Michael Milone, Enxiu Wang
  • Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
    Patent number: 10577417
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: March 3, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Michael C. Milone, Huijuan Song, Enxiu Wang, Qilong Wu
  • TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
    Publication number: 20180022795
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Application
    Filed: July 24, 2017
    Publication date: January 25, 2018
    Inventors: Michael Milone, Enxiu Wang
  • TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
    Publication number: 20170260268
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Application
    Filed: September 17, 2015
    Publication date: September 14, 2017
    Inventors: Gregory BEATTY, Boris ENGELS, Neeraja IDAMAKANTI, Carl H JUNE, Andreas LOEW, Michael C. MILONE, Huijuan SONG, Enxiu WANG, Qilong WU
  • Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
    Patent number: 9745368
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: August 29, 2017
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Michael C. Milone, Enxiu Wang
  • TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
    Publication number: 20140322183
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Application
    Filed: March 15, 2014
    Publication date: October 30, 2014
    Inventors: Michael C. Milone, Enxiu Wang